Royalty Pharma agreed to co-fund Johnson & Johnson’s $500 million autoimmune antibody program, marking another expansion of Royalty’s royalty-backed development model in immunology. The arrangement provides J&J with financing support over the next two years while Royalty’s participation ties to the development and value creation pathway for a chronic autoimmune therapy. The deal underscores sustained capital-market appetite for autoimmune assets, where late-stage clinical data and differentiation versus existing biologics often drive investor attention. It also reflects the continued use of structured financing to reduce upfront balance-sheet exposure while maintaining development continuity. For J&J, the financing adds flexibility for program execution in a category where payers increasingly scrutinize comparative effectiveness, safety and dosing convenience.